Oragenics (NYSEAMERICAN:OGEN) Shares Down 1.5% – What’s Next?

Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN) traded down 1.5% on Monday . The company traded as low as $0.54 and last traded at $0.5411. Approximately 8,676 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 30,866 shares. The stock had previously closed at $0.5496.

Oragenics Stock Down 1.9%

The company has a 50-day moving average of $0.59 and a 200-day moving average of $0.69. The company has a market cap of $2.39 million, a PE ratio of -0.02 and a beta of 1.25.

Oragenics (NYSEAMERICAN:OGEN) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.51) earnings per share for the quarter.

Institutional Investors Weigh In On Oragenics

A number of institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in shares of Oragenics during the 4th quarter worth approximately $26,000. DRW Securities LLC grew its holdings in shares of Oragenics by 82.4% in the fourth quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock valued at $88,000 after acquiring an additional 50,900 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of Oragenics by 7,374.0% during the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after acquiring an additional 15,338 shares during the last quarter. 18.71% of the stock is owned by institutional investors.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.